HCG Cancer Centre, Bengaluru, has unveiled the CyberKnife S7 System, a cutting-edge, AI-powered, fully automated treatment delivery system with real-time motion adaptation.
In a press statement on Tuesday, the company informed that the new system, which promises to revolutionise the treatment of cancerous and non-cancerous tumours, was launched by Dr. B. S. Ajaikumar, Executive Chairman of Healthcare Global Enterprises Limited (HCG), and Raj Gore, CEO of HCG.
HCG has been a pioneer of CyberKnife technology in India since 2009 and has successfully treated over 7,500 patients, including nearly 5,635 in Bengaluru alone. The new CyberKnife S7 System offers a non-invasive treatment alternative for patients with tumors in various parts of the body, including the brain, lung, spine, prostate, and abdomen. It provides renewed hope for those with inoperable or complex tumors, as well as patients with recurrent or metastatic lesions.
Dr. B. S. Ajaikumar expressed his pride in HCG’s leadership in advanced cancer treatment. He remarked, “We were one of the first in India to adopt CyberKnife technology. The launch of the CyberKnife S7 reinforces our mission to deliver precise, non-invasive therapies that effectively target both cancerous and non-cancerous tumors.”
Raj Gore emphasised the significance of this milestone for HCG, stating, “The CyberKnife S7 offers unparalleled precision, allowing for higher doses and fewer treatment sessions without compromising speed or patient comfort. This aligns with our strategic goal of improving patient outcomes and expanding our treatment capabilities.”
Manisha Kumar, Regional Chief Operating Officer for Karnataka, highlighted the transformative impact of the new system, noting, “The CyberKnife S7 System transforms radiation therapy with its impressive speed, accuracy, and real-time target tracking. This upgrade will strengthen HCG's reputation as a leader in cancer treatment.”
